Filing Flows › Seres Therapeutics (MCRB) › R&D spending
Seres Therapeutics (MCRB) R&D spending by quarter
Seres Therapeutics' R&D spending was $5.6M in Q3 2026 (third quarter 2026), -39% from Q2 2026. Over the last 5 quarters it ranged from $5.6M (Q3 2026) to $13.2M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.6M | -39% | -56% |
| Q2 2026 | $9.1M | -31% | — |
| Q1 2026 | $13.2M | +13% | — |
| Q4 2025 | $11.7M | -7% | — |
| Q3 2025 | $12.6M | — | — |
Q3 2026 at a glance
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Seres Therapeutics' R&D spending?
Seres Therapeutics' R&D spending was $5.6M in Q3 2026 (third quarter 2026), -39% from Q2 2026.
How has Seres Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $5.6M (Q3 2026) to $13.2M (Q1 2026).